Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06789159 · ClinicalTrials.gov registry record · Phase 1
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
A Phase 1 study of Diffuse Large B-Cell Lymphoma-Refractory and Diffuse Large B Cell Lymphoma Relapsed, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06789159 is a Phase 1 study of Diffuse Large B-Cell Lymphoma-Refractory and Diffuse Large B Cell Lymphoma Relapsed that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06789159, a Phase 1 study of Diffuse Large B-Cell Lymphoma-Refractory and Diffuse Large B Cell Lymphoma Relapsed, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg/day, 1200 mg/day, 1800 mg/day for 28 days (cycle), until progression or toxicity.
Conditions Studied
Interventions
- DRUG VK-2019
Study Locations (1)
Pennsylvania
- Honickman Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06789159
The ClinicalTrials.gov registry entry for NCT06789159 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diffuse Large B-Cell Lymphoma-Refractory appearing as the primary indexed condition, and to 1 intervention - of which VK-2019 is the first listed.
NCT06789159 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06789159 about?
NCT06789159 is a clinical study titled "A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)". This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg/day, 1200 mg/day, 1800 mg/day for 28 days (cycle), until progression or toxicity.
What is the current status of trial NCT06789159?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-05-22. Estimated completion is 2028-10-01.
What conditions does trial NCT06789159 study?
This clinical trial studies the following conditions: Diffuse Large B-Cell Lymphoma-Refractory, Diffuse Large B Cell Lymphoma Relapsed, Epstein-Barr Virus (EBV) Infection.
What interventions are being tested in trial NCT06789159?
The interventions under investigation include: VK-2019 (DRUG).
Who is sponsoring clinical trial NCT06789159?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06789159 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B-Cell Lymphoma-Refractory
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Diffuse Large B-Cell Lymphoma-Refractory
All registered trials for this condition
Diffuse Large B Cell Lymphoma Relapsed
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.